Pyrazoles as potential anti-obesity agents

Research Journal of Chemistry and Environment

Volumn 15, Issue 3, 2011, Pages 90-103

  Gupta, Girish Kumar ^a   Kumar, Vikas ^a   Kumar, Vinod ^a  

^a MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

Author keywords

Anti obesity agents; Pyrazoles

Indexed keywords

AROMATIC HYDROCARBON; BIOACTIVITY; DRUG DEVELOPMENT; LITERATURE REVIEW; MEDICINE; OBESITY;

EID: 80053190201     PISSN: 09720626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Bray G. A., Obesity the Disease, J. Med. Chem., 49, 4001-4007 (2006)
2. Carpino P.A. and Hadcock J.R., Burger's Medicinal Chemistry and Drug Discovery; Abraham D.J., 6th ed., John Wiley and Sons, Inc., (2003)
3. Mertens I.L. and Gaal L.F.V., Promising New Approaches to the Management of Obesity, Drugs, 60, 1-9 (2000) (Pubitemid 30598816)
4. Johnson P.R., Greenwood M.R.C., Horwitz B.A. and Stern J.S., Animal Models of Obesity: Genetic Aspects, Annu. Rev. Nutr., 11, 325-353 (1991) (Pubitemid 21903833)
5. Collins P. and Williams G., Drug treatment of obesity: from past failures to future successes, Br J Clin Pharmacol., 51, 13-25 (2000)
6. Barsh G.S., Farooqi I.S. and O'Rahilly S., Nature, 505, 644-651 (2000)
7. Alvarado M., Goya P., Macias-Gonzalez M., Pavon F. J., Serrano A., Jagerovic N., Elguero J., Gutierrez-Rodriguez A., Garcia-Granda S., Suardiaz M. and Fonseca F.R., Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents, Bioorg. Med. Chem., 16, 10098-10105 (2008)
8. Kanatani A. et al, The Novel Neuropeptide Y Y1 Receptor Antagonist J-104870: A Potent Feeding Suppressant with Oral Bioavailability, Biochem. Biophys. Res. Commun., 266, 88-91 (1999) (Pubitemid 30028772)
9. Plummer C.W., Finke P.E., Mills S.G., Wang J., Tong X. and Doss G.A., Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists, Bioorg. Med. Chem. Lett., 15, 1441-1446 (2005) (Pubitemid 40269008)
10. LoVerme J., Duranti A., Tontini A., Spadoni G., Mor M., Rivara S., Stella N., Xu C., Tarzia G. and Piomelli D., Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice, Bioorg. Med. Chem. Lett., 19, 639-643 (2009)
11. Jagerovic N. et al, Discovery of 5-(4-Chlorophenyl)-1-(2,4- dichlorophenyl)-3-hexyl-1H-1,2,4-triazole, a Novel in Vivo Cannabinoid Antagonist Containing a 1,2,4-Triazole Motif, J. Med., Chem., 47, 2939-2942 (2004) (Pubitemid 38656746)
12. Tao M. et al, Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach, Eur. J. Med. Chem., 45, 1133-1139 (2010)
13. Vemuri V.K., Janero D.R. and Makriyannis A., Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome, Physiol. Behav., 93, 671-686 (2008) (Pubitemid 351410420)
14. Lange J.H.M., Hartog A.P., Martina A.W., Vliet B.J. and Krus C.G., Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists, Bioorg. Med. Chem. Lett., 19, 5675-5678 (2009)
15. Das S.K. and Chakrabarti R., Antiobesity Therapy: Emerging Drugs and Targets, Curr. Med. Chem., 13, 1429-1460 (2006)
16. Park H.A., Lee K., Park S.J., Ahn B., Lee J.C., Cho H.Y. and Lee K.I., Identification of antitumor activity of pyrazole oxime ether, Bioorg. Med. Chem. Lett., 15, 3307-3312 (2005) (Pubitemid 40799080)
17. Manfredini S. et al, Pyrazole-related nucleosides, Synthesis and antiviral/ antitumor activity of some substituted pyrazole and pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides, J. Med. Chem., 35, 917-924 (1992)
18. Tanitame A., Oyamada Y., Ofuji K., Fujimoto M., Iwai N., Hiyama Y., Suzuki K., Ito H., Wachi M. and Yamagishi J., Synthesis and Antibacterial Activity of a Novel Series of Potent DNA Gyrase Inhibitors, Pyrazole Derivatives, J. Med. Chem. 47, 3693-3696 (2004) (Pubitemid 38822030)
19. Kucukguzel S.G., Rollas S., Erdeniz H., Kiraz M., Ekinci A.C. and Vidin A., Synthesis, characterization and pharmacological properties of some 4-arylhydrazono-2- pyrazoline-5-one derivatives obtained from heterocyclic amines, Eur. J .Med. Chem., 35, 761-771 (2000) (Pubitemid 30490284)
20. Genin M.J. et al, Substituent Effects on the Antibacterial Activity of Nitrogen?Carbon-Linked (Azolylphenyl) oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms Haemophilus influenzae and Moraxella catarrhalis, J. Med. Chem., 43, 953-970 (2000) (Pubitemid 30152301)
21. Bekhit A.A. et al, Design and synthesis of some substituted 1H-pyrazolyl-thiazolo [4,5-d]pyrimidines as anti-inflammatory- antimicrobial Agents, Eur. J. Med. Chem., 38, 27-36 (2003) (Pubitemid 36197852)
22. Penning T.D. et al, Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1Hpyrazol- 1-yl]benzenesulfonamide (SC-58635, Celecoxib), J. Med. Chem., 40, 1347-1365 (1997) (Pubitemid 27198082)
23. Amir M. and Kumar S., Synthesis and anti-inflamatory, analgesic, ulcerogenic and lipid peroxidation activities of 3,5- dimethyl pyrazole, 3-methyl pyrazole-5-one, 3,5-disubstituted pyrazolines, Indian J. Chem., 44, 2532-2537 (2005) (Pubitemid 43127857)
24. Sridhar R., Perumal P.T., Etti S., Shanmugam G., Ponnuswamy M.N., Prabavathy V.R. and Mathivanan N., Design, synthesis and anti-microbial activity of 1H-pyrazole carboxylates, Bioorg. Med. Chem. Lett., 14, 6035-6040 (2004) (Pubitemid 39534360)
25. Kees K.L. et al, New Potent Antihyperglycemic Agents in db/db Mice: Synthesis and Structure?Activity Relationship Studies of (4-Substituted benzyl)(trifluoromethyl) pyrazoles and - pyrazolones, J. Med. Chem., 39, 3920-3928 (1996) (Pubitemid 26327429)
26. Bebernitz G.R. et al, The Effect of 1,3-Diaryl-[1H]-pyrazole- 4-acetamides on Glucose Utilization in ob/ob Mice, J. Med. Chem., 44, 2601 (2001)
27. Alvarado M. et al, Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents, Bioorg. Med. Chem., 16, 10098-10105 (2008)
28. Lange J.H.M. and Kruse C.G., Keynote review: medicinal chemistry strategies to CB1 cannabioid receptor antagonists, Drug Discov Today., 10, 693-702 (2005) (Pubitemid 40724551)
29. Strader C.D., Hwa J.J., Heek M.V. and Parker E.M., Novel molecular targets for the treatment of obesity, Drug Discov Today, 3, 250-256 (1998) (Pubitemid 28255329)
30. Hertzog D.L. et al, The discovery and optimization of pyrimidinone-containing MCH R1 antagonists, Bioorg. Med.Chem. Lett., 16, 4723-4727 (2006) (Pubitemid 44175869)
31. He S. et al, Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity, Bioorg. Med. Chem. Lett., 20, 4399-4405 (2010)
32. Sawa M. and Harada H., Recent developments in the design of orally bioavailable ?3-adrenergic receptor agonists, Curr. Med. Chem., 13, 25-37 (2006)
33. Smith B.M. et al, Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity, J. Med. Chem., 51, 305-313 (2008)
34. Heal D.J. et al, Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders, Pharmacol. Ther., 117, 207-231 (2008)
35. Harp J.B., An assessment of the efficacy and safety of orlistat for the long-term management of obesity, J. Nutr. Biochem., 9, 516-521 (1998) (Pubitemid 28470627)
36. Luque C.A. et al, The discovery and status of sibutramine as an anti-obesity drug, Eur. J. Pharmacol., 440, 119-128 (2002) (Pubitemid 34458019)
37. Hancock A.A. et al, Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist, Eur. J. Pharmacol., 487, 183-197 (2004) (Pubitemid 38368996)
38. Szewczyk J.R. and Laudeman C., CCK1R agonists: a promising target for the pharmacological treatment of obesity, Curr. Top. Med. Chem., 3, 837-854 (2003)
39. Gutzwiller J.P., Degen L., Heuss L. and Beglinger C., Glucagon-like peptide 1 (GLP-1) and eating, Physiol. Behav., 82, 17-19 (2004) (Pubitemid 38968502)
40. Zhao G. et al, Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor, J. Med. Chem., 51, 380-383 (2008) (Pubitemid 351252263)
41. Yu M. et al, Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity, Bioorg. Med. Chem. Lett., 20, 1758-1762 (2010)
42. Bhattarai B.R. et al, Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects, Bioorg. Med. Chem. Lett., 19, 6161-6165 (2009)
43. Carek P.J. and Dickerson L.M., Current Concepts in the Pharmacological Management of Obesity, Drugs, 57, 883-904 (1999) (Pubitemid 29313201)
44. Iversen L., Cannabis and the brain, Brain, 126, 1252-1270 (2003) (Pubitemid 36644373)
45. Patrik G.L., An Introduction to medicinal Chemistry, 4th ed., Oxford University Press, New York, 101 (2009)
46. Colombo G., Agabio R., Diaz G., Lobina C., Reali R. and Gessa G. L., Appetite suppression and weight loss after the cannabinoid antagonist SR141716, Life Sci., 63, 113-117 (1998) (Pubitemid 28378339)
47. Rinaldi-Carmona M. et al, SR1417 16A, a potent and selective antagonist of the brain cannabinoid receptor, FEBS Letters, 350, 240-244 (1994) (Pubitemid 24268029)
48. Ye M. and Dawson M.I., Studies of cannabinoid-1 receptor antagonists for the treatment of obesity: Hologram QSAR model for biarylpyrazolyl oxadiazole ligands, Bioorg. Med. Chem. Lett., 19, 3310-3315 (2009)
49. Lee S.H., Seo H.J., Kim M.J., Kang S.Y., Song K., Lee S., Jung M.E., Kim J. and Lee J., Oxadiazole-diarylpyrazole-4- carboxamides as cannabinoid CB1 receptor ligands, Bioorg. Med. Chem. Lett., 19, 1899-1902 (2009)
50. Dow R.L. et al, Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A, Part I: Potent, orally-active 1, 4-disubstituted imidazoles, Bioorg. Med. Chem. Lett., 19, 5351-5354 (2009)
51. Kang S.Y., Lee S., Seo H.J., Jung M.E., Ahn K., Kim J. and Lee J., Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists, Bioorg. Med. Chem. Lett., 18, 2385-2389 (2008) (Pubitemid 351442896)
52. Seo H.J. et al, Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand, Bioorg. Med. Chem. Lett., 18, 1149- 1162 (2010)
53. Srivastava B.K. et al, Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4- methyl-1H-pyrazole-3-carboxylicacid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonist, Bioorg. Med. Chem. Lett., 18, 3882-3886 (2008)
54. Srivastava B.K. et al, Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4, 5-dihydro-1H-pyrazole-1- caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole, Bioorg. Med. Chem. Lett., 18, 963-968 (2008) (Pubitemid 351187882)
55. Menozzi G., Fossa P., Cichero E., Spallarossa A., Ranise A. and Mosti L., Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant, Eur. J. Med. Chem., 43, 2627-2638 (2008)
56. Lange J.H., Coolen H.K., van Stuivenberg H.H., Dijksman J.A., Herremans A.H. and Ronken E., Synthesis, biological properties and molecular modeling investigations of novel 3,4- diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists, J Med. Chem., 47, 627-643 (2004) (Pubitemid 38129720)
57. Solvay's obesity candidate treatment advances in phase II clinical trials. http://www.solvaypharmaceuticals.com/ static/wma/pdf/9/3/1/3/ 20061208SLV319, December 08 (2006)
58. Rinaldi-Carmona M., Barth F., Congy C., Martinez S., Oustric D. and Perio A., SR147778[5-(4-bromophenyl)-1-(2,4- dichlorophenyl)-4-ethyl-N-(1- piperidinyl)-1H-pyrazole-3 carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization, J. Pharmacol. Exp. Ther., 310, 905-914 (2004) (Pubitemid 39108910)
59. Srivastava B.K., Soni R., Patel J.Z., Joharapurkar A., Sadhwani N., Kshirsagar S., Mishra B., Takale V., Gupta S., Pandya P., Kapadnis P., Solanki M., Patel H., Mitra P., Jain M.R. and Patel P.R., Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a cb1 receptor antagonist with in vivo antiobesity effect, Bioorg. Med. Chem. Lett., 19, 2546-2550 (2009)
60. Song K., Kim M.J., Seo H.J., Lee S., Jung M.E., Kim S., Kim J. and Lee J., Synthesis and structure activity relationship of novel diarylpyrazole imide analogues as CB1 cannabinoid receptor ligands, Bioorg. Med. Chem. Lett., 17, 3080-3092 (2009)
61. Makriyannis A. and Liu Q., PCT Patent WO2003020217, March 13, 2003, Chem. Abstr., 138, 238177 (2003)
62. Dow R.L., PCT Patent WO2004035566, April 29, 2004, Chem. Abstr., 140, 357343 (2004)
63. Chambers A.P., Sharkey K.A. and Koopmans H.S., Cannabinoid (CB) 1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat, Physiol. Behav., 82, 863-869 (2004) (Pubitemid 39297082)
64. Hildebrandt A.L., Kelly-Sullivan D.M. and Black S.C., Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice, Eur. J. Pharmacol., 462, 125-132 (2003) (Pubitemid 36183743)
65. Lee H.K., Choi E.B. and Pak C.S., The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents, Curr. Top. Med. Chem., 9, 482-503 (2009)
66. Tseng S.L. et al, Bioisosteric replacement of the pyrazole 5- aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H- pyrazole-3-carboxamide (SR 1417- 16A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists, J. Med. Chem., 51, 5397-5412 (2008)
67. Tai C.L. et al, Design, synthesis, and biological evaluation of novel alkenylthiophenes as potent and selective CB1 cannabinoid receptor antagonists, Org. Biomol.Chem., 6, 447-450 (2008)
68. Katoch-Rouse R., Pavlova R., Caulder O.A., Hoffman T., Mukhin A.F. and Horti A.G., Synthesis, structure activity relationship, and evaluation of SR 141716 analogs: Development of central cannabinoid receptor ligands with lower lipophilicity, J. Med. Chem., 46, 642-645 (2003) (Pubitemid 36182766)
69. Chu C.M., Hung M.S., Hsieh M.T., Kuo C.W., Suja T.D., Song J.S., Chiu H.H., Chao Y.S. and Shia K.S., Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant, A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists, Org. Biomol. Chem., 6, 3399-3407 (2008)
70. Lee S.H. et al, Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity, J. Med. Chem., 51, 7216-7233 (2008)
71. Kang S.Y., Lee S.H., Seo H.J., Jung M.E., Ahn K., Kim J. and Lee J., Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. Bioorg. Med. Chem. Lett., 18, 2385-2388 (2008)
72. Dow R. L., U. S. Patent 2004/0077650, April 22 (2004)
73. Dow R. L., Hammond, M. WO 2004/052864, June 24 (2004)
74. Srivastava B.K. et al, Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model, J. Med. Chem., 50, 5951(2007)
75. Torrens-Jover A. and Yenes-Minguez S., WO 2007/009711, January 25 (2007)
76. Torrens-Jover A. and Yenes-Minguez S., WO 2007/009722, January 25 (2007)
77. Torrens-Jover A. and Yenes-Minguez S., WO 2007/009697, January 25 (2007)
78. Torrens-Jover A. and Yenes-Minguez S., WO 2007/009709, January 25 (2007)
79. Torrens-Jover A. and Yenes-Minguez S., WO 2007/009724, January 25 (2007)
80. Torrens-Jover A. and Yenes-Minguez S., WO 2007/009720, January 25 (2007)
81. Torrens-Jover A. and Yenes-Minguez S., WO 2007/009721, January 25 (2007)
82. Torrens-Jover A. and Yenes-Minguez S., WO 2007/0097 12, January 25 (2007)
83. Buschmann H. et al, WO 2007/009689, January 25 (2007)
84. Torrens-Jover A. and Yenes-Minguez S., WO 2007/009723, January 25 (2007)
85. Mcelroy J.F. and Chorvat R. J., WO 2009/033125, March 12, (2009)
86. Cooper M. et al, Noeregaard P. K., Murray A. and Bjurling E., WO 2008/075012, June 26 (2008)
87. Cuberes R., Frigola J. and Gutierrez B., WO 2005077911, Aug 25 (2005)
88. Jagerovic N. et al, CB1 Cannabinoid Antagonists: Structure- Activity Relationships and Potential Therapeutic Applications, Curr. Top. Med. Chem., 8, 205-230 (2008) (Pubitemid 351795770)
89. Lee J. et al, Discovery of 2-(4-((1H-1,2,4-triazol-1- yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3- yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist, Bioorg. Med. Chem., 18, 6377-6388 (2010)
90. Chen W. et al, Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models, Eur. J. Pharmacol, 637, 178-185 (2010)
91. Yan L. et al, Discovery of N-[(4R)6-(4-Chlorophenyl)-7-(2,4- dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2Hpyrano [2,3-b]pyridin- 4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist for the Treatment of Obesity, J. Med. Chem., 53, 4028-4037 (2010)
92. Brandt T.A. et al, Development of two synthetic routes to CE- 178,253, a CB1 antagonist for the treatment of obesity, Tetrahedron, 65, 3292-3304 (2009)
93. Ruiu S. et al, Synthesis and characterization of NESS-0327: A novel putative antagonist of CB1 cannabinoid receptor, J. Pharmacol. Exp. Ther., 306, 363-370 (2003) (Pubitemid 36734393)
94. Erondu N. et al, Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell. Metab., 4, 275-282 (2006) (Pubitemid 44430911)
95. Carpino P.A. et al, New bicyclic cannabinoid receptor- 1 (CB1-R) antagonists, Bioorg. Med. Chem. Lett., 16, 731 (2006)
96. Lagu B., Liotta F., Pan M., Wachter M.P. and Xia M., WO 2005/095353, October 13, (2005)
97. Souers A.J. et al, Identification of 2-(4-Benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an Orally Efficacious Melanin-Concentrating Hormone Receptor 1 Antagonist for the Treatment of Obesity, J.Med. Chem., 48, 1318 (2005)
98. Souers A.J. et al, Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity, Bioorg. Med. Chem. Lett., 15, 2752-2757 (2005) (Pubitemid 40732213)
99. Jeon M.K. and Cheon H.G., Promising Strategies for Obesity Pharmacotherapy: Melanocortin-4 (MC-4) Receptor Agonists and Melanin Concentrating Hormone (MCH) Receptor-1 Antagonists, Curr. Top. Med. Chem., 9, 504-538 (2009)
100. Vasudevan A. et al, Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists, Bioorg. Med. Chem. Lett., 15, 5293-5297 (2005) (Pubitemid 41463667)
101. Fukami T., Fukuroda T., Kanatani A. and Ihara M., PCT Patent WO1998/9827063, Chem. Abstr., 129, 95488 (1998)
102. Fukami T., Fukuroda T., Kanatani A. and Ihara M., PCT Patent WO1998/9825907, Chem. Abstr., 129, 81725 (1998)
103. Parker E., Heek M.V. and Stamford A., Neuropeptide Y receptors as targets for anti-obesity drug development:perspective and current status, Eur. J. Pharmacol., 440, 173-187 (2002) (Pubitemid 34458022)
104. Dozio E., Ruscica M., Motta M. and Magni P., Hypothalamic Neuropeptide Systems as Targets for Potential Anti-Obesity Drugs, Mini Rev Med Chem., 7, 11-19 (2007) (Pubitemid 46062369)
105. Kordik C.P., Luo C., Zanoni B.C., Dax S.L., McNally J.J., Lovenberg T.W., Wilson S.J. and Reitz A.B., Aminopyrazoles with high affinity for the human neuropeptide Y5 receptor, Bioorg. Med. Chem. Lett., 11, 2283-2286 (2001) (Pubitemid 32781683)
106. Kordik C.P. et al, Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity, Bioorg. Med. Chem. Lett., 11, 2287-2290 (2001) (Pubitemid 32781684)
107. Haga Y. et al, Discovery of trans-N-[1-(2-fluorophenyl)-3- pyrazolyl]-3-oxospiro-[6-azaisobenzofuran-1(3H),10-cyclohexane]- 40-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist, Bioorg. Med. Chem., 17, 6971-6982 (2009)
108. Lee J., Song K.S., Kang J., Lee S.H. and Lee J., New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy, Curr. Top. Med. Chem., 9, 564-596 (2009)
109. Sato N. et al, Design and Synthesis of the Potent, Orally Available, Brain-Penetrable Arylpyrazole Class of Neuropeptide Y5 Receptor Antagonists, J. Med. Chem., 46, 666-669 (2003) (Pubitemid 36258855)
110. Henke B.R. et al, 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A Agonists That Demonstrate Oral Activity as Satiety Agents, J. Med. Chem., 39, 2655 (1996)
111. Henke B. R. et al, Optimization of 3-(1H-Indazol-3- ylmethyl)-1,5- benzodiazepines as Potent, Orally Active CCK-A Agonists, J. Med. Chem., 40, 2706 (1997)
112. Jabbour S.A. and Goldstein B.J., Sodium glucose cotransporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes, Int. J. Clin. Pract., 62, 1279-1284 (2008). (Pubitemid 351977622)